Bacillus anthracis is a gram-positive endospore-forming bacterium that causes the disease anthrax in livestock, wildlife, and humans. Because of its hardy spores,
B. anthracis can survive for extended periods in the environment, a trait that likely contributed to the successful global spread of this organism (
1). The mostly dormant life cycle of
B. anthracis and its relatively recent emergence as a pathogen have resulted in a genome that is highly clonal, with little genetic variation among even the most distantly related strains (
2–4).
Anthrax is most commonly contracted by exposure to contaminated animal products, such as skins, wool, or meat; its symptoms vary in severity depending on the route of infection. Cutaneous anthrax, the most common manifestation of disease, accounts for 95% of cases, whereas pulmonary and gastrointestinal anthrax are much less common and follow inhalation or ingestion of spores, respectively. Inhalational anthrax is rare but particularly deadly, with up to a 90% fatality rate (
5).
In 2000, a novel form of cutaneous anthrax, termed injectional anthrax, was proposed after anthrax was diagnosed in a heroin “skin popper” (one who injects the drug beneath the skin, rather than into a vein) from Norway on postmortem examination (
6). Injectional anthrax symptoms are more severe than those of cutaneous anthrax and are typified by severe soft tissue infection at the injection site, which can progress to septic shock, meningitis, and death (
7). The origin of anthrax in the Norwegian heroin user was never identified, although contaminated heroin was suspected (
6). This case was the first to demonstrate this previously unrecognized route of
B. anthracis infection.
In December 2009, two cases of injectional anthrax were diagnosed in heroin users in Scotland after
B. anthracis was detected in blood cultures (
8). These cases marked the beginning of an emerging anthrax outbreak among European heroin users. Over the following months, 14 anthrax deaths were confirmed and 119 anthrax cases were suspected (
9), leading to increasing media attention as the severity of this outbreak became more apparent. This attention was spurred by 3 factors. First,
B. anthracis is not found naturally in Scotland, and human cases of anthrax in Europe are extremely rare, with only 3 cases of anthrax notified in Europe in 2008 (
10). Second, the pathology of injectional anthrax is especially devastating (
11,12). Third, anthrax cases appeared to befall only an ostensibly targeted population of persons, leading to initial suggestions of deliberate contamination of the heroin supply. Although investigations were unable to show nefarious intent, the mode of contamination with
B. anthracis spores remained elusive because of an inability to culture
B. anthracis from, or detect
B. anthracis DNA in, suspected contaminated heroin (
9).
In the current study, we applied a molecular phylogeographic approach to identify the likely origin of the
B. anthracis spores responsible for the 2009–2010 outbreak in Europe. We used canonical single-nucleotide polymorphism (canSNP) genotyping against heroin anthrax samples and an extensive collection of diverse worldwide samples (
1,13) and whole genome sequencing techniques to determine a possible origin for the
B. anthracis spores responsible for this outbreak.